First multicenter study of modified release phosphatidylcholine LT-02 in ulcerative colitis: A randomized, placebo-controlled trial in mesalazine-refractory courses

American Journal of Gastroenterology

Volumn 109, Issue 7, 2014, Pages 1041-1051

  Karner, Max ^a,b   Kocjan, Andreas ^c   Stein, Juergen ^d   Schreiber, Stefan ^e   Von Boyen, Georg ^f,g   Uebel, Peter ^h   Schmidt, Carsten ⁱ   Kupcinskas, Limas ^j   Dina, Ion ^k,l   Zuelch, Frank ^m   Keilhauer, Gerhard ^m   Stremmel, Wolfgang ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Department of Medicine Gastroenterology Viernheim Hospital   (Germany)

^c Internistische Facharztpraxis ^*  (Germany)

^d Crohn Colitis Center Frankfurt   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY HOSPITAL ULM   (Germany)

^g Kliniken Landkreis Sigmaringen   (Germany)

^h Internistische Gemeinschaftspraxis   (Germany)

ⁱ JENA UNIVERSITY HOSPITAL   (Germany)

^j LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^k SC Endocenter Medicina Integrativa   (Romania)

^l CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^m Lynx Therapeutics GmbH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LT 02; MESALAZINE; PHOSPHATIDYLCHOLINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOODY DIARRHEA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; GERMANY; GOOD MANUFACTURING PRACTICE; HISTOLOGY; HUMAN; LITHUANIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; ROMANIA; SIMPLE CLINICAL COLITIS ACTIVITY INDEX; TREATMENT DURATION; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HUMANS; LITHUANIA; MALE; MESALAMINE; MIDDLE AGED; PHOSPHATIDYLCHOLINES; PLACEBOS; ROMANIA; TREATMENT OUTCOME;

EID: 84903897973     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.104     Document Type: Article

References (27)

1. Lofus EV Jr. Clinical epidemiology of inf ammatory bowel disease: incidence, prevalence, and environmental inf uences. Gastroenterology 2004;126:1504-17.
2. Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev 2008:3: CD007216.
3. Shibolet O, Regushevskaya E, Brezis M et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005:1: CD004277.
4. DeVries HS, vanOijen MG, deJong DJ. Serious events with inf iximab in patients with inf ammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf 2008;31:1135-44.
5. Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of inf iximab for the treatment of inf ammatory bowel disease: a single-center cohort study. Gut 2009;58:501-8.
6. Hoie O, Wolters FL, Riis L et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007;132:507-15.
7. DeSchryver-Kecskemeti K, Eliakim R, Carroll S et al. In testin al su rfactan t-like material. A novel secretory product of the rat enterocyte. J Clin Invest 1989;84:1355-61.
8. Lichtenberger LM. The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol 1995;57:565-83.
9. Stremmel W, Hanemann A, Braun A et al. Delayed release phosphatidyl-choline as new therapeutic drug for ulcerative colitis-a review of three clinical trials. Expert Opin Investig Drugs 2010;Dec:19:1623-30.
10. Ehehalt R, Wagenblast J, Erben G et al. Phosphatidylcholine and lysophos-phatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry. Scand J Gastroenterol 2004;39:737-42.
11. Braun A, Treede I, Gotthardt D et al. Alterations of phospholipid concen tration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Infamm Bowel Dis 2009;15:1705-20.
12. Podolsky DK. Inflamatory bowel disease. N Engl J Med 2002;347:417-29.
13. Treede I, Braun A, Jeliaskova P et al. TNF-alpha-induced up-regulation of pro-inf ammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. BMC Gastroenterol 2009;9:53.
14. Treede I, Braun A, Sparla R et al. Anti-inf ammatory effects of phosphatidyl-choline. J Biol Chem 2007;282:27155-64.
15. Braun A, Schönfeld U, Welsch T et al. Reduced hydrophobicity of the colonic mucosal surface in ulcerative colitis as a hint at a physicochemical barrier defect. Int J Colorectal Dis 2011; 26: 989-98.
16. Gibson PR, Muir JG. Reinforcing the mucus: a new therapeutic approach for ulcerative colitis?. 2005;54:900-3.
17. Crof NM. Phospholipid in UC: novel, safe and works - is it too good to be true? Gastroenterology 2006;130:1003-4; discussion 1004-5.
18. Stremmel W, Merle U, Zahn A et al. Retarded release phosphatidylcholine benefts patients with chronic active ulcerative colitis. Gut 2005;54:966-71.
19. Stremmel W, Braun A, Hanemann A et al. Delayed release phosphatidyl-holine in chronic-active ulcerative colitis: a randomized, double-blinded, dose fnding study. J Clin Gastroenterol 2010;44:e101-7.
20. Stremmel W, Ehehalt R, Autschbach F et al. E f cacy of retarded release phosphatidylcholine for treatment of chronic, steroid refractory ulcerative colitis. Ann Intern Med 2007;147:603-10.
21. Stange EF, Travis SP, Vermeire S et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Def nitions and diagnosis of the European Crohn's and Colitis Organisation (ECCO). J Crohns Colitis 2008; 2: 1-23.
22. Walmsley RS, Ayres RC, Pounder RE et al. A simple clinical colitis activity index. Gut 1998;43:29-32.
23. Higgins PD, Leung J, Schwartz M et al. The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis. Aliment Pharmacol Ter 2007;25:333-42.
24. Higgins PD, Schwartz M, Mapili J et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol 2005;100:355-61.
25. Jowett SL, Seal CJ, Phillips E et al. D e f ning relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol 2003; 38: 164-71.
26. Higgins PD, Schwartz M, Mapili J et al. P atien t d ef ned dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005;54:782-8.
27. Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat 2008;7:93-106.